Biotech Co. Wants To Appeal Red Cross Antitrust Immunity

By Matthew Perlman · May 6, 2024, 8:35 PM EDT

A biotech company has told a Massachusetts federal court that giving the American Red Cross immunity from claims that it smothered competition in the platelet bacteria mitigation market is unprecedented and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

Verax Biomedical Inc. v. American National Red Cross

Case Number

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

February 14, 2023

Recent Articles By Matthew

November 21, 2024
Nurse Staffing Exec Can't Trim Fraud Charge In Antitrust Case
November 20, 2024
PBMs Sue To Block FTC's In-House Insulin Pricing Case
November 07, 2024
Teva Can't End Inhaler Antitrust Suit But Gets Claim Nixed
November 01, 2024
Health Data Co. Urges 4th Circ. To Keep Access Open
October 31, 2024
Drug Cos. To Pay $49M For State-Led Generic Pricing Claims
October 30, 2024
Ohio PBM Case Will Wait For High Court Ruling
October 24, 2024
PBMs Want Separate FTC Hearings Over Insulin Prices
October 21, 2024
NC Justices Revive Challenge To Hospital Competition Law
October 15, 2024
FTC Wants More Info On $1.36B Home Healthcare Deal
October 07, 2024
Justices Won't Hear Shkreli's Bid To Undo $64M Disgorgement